Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.740 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.740
Bid (Size) 4.670 (200)
Ask (Size) 5.230 (200)
Prev. Close 4.740
Today's Range 4.740 - 4.740
52wk Range 3.940 - 8.290
Shares Outstanding 9,947,915
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces $11.1 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire

Performance

YTD
-16.1%
-16.1%
1 Month
+2.6%
+2.6%
3 Month
-20.5%
-20.5%
6 Month
-16.6%
-16.6%
1 Year
-28.3%
-28.3%

More News

Read More
News headline image
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Coya Therapeutics Announces Proposed Public Offering of Common Stock
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
What's Going On With Coya Therapeutics Stock? ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025
Via ACCESS Newswire
News headline image
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
Via ACCESS Newswire

Frequently Asked Questions

Is Coya Therapeutics, Inc. - Common Stock publicly traded?
Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Coya Therapeutics, Inc. - Common Stock trade on?
Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?
The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market
What is the current price of Coya Therapeutics, Inc. - Common Stock?
The current price of Coya Therapeutics, Inc. - Common Stock is 4.740
When was Coya Therapeutics, Inc. - Common Stock last traded?
The last trade of Coya Therapeutics, Inc. - Common Stock was at 02/12/26 04:00 PM ET
What is the market capitalization of Coya Therapeutics, Inc. - Common Stock?
The market capitalization of Coya Therapeutics, Inc. - Common Stock is 47.15M
How many shares of Coya Therapeutics, Inc. - Common Stock are outstanding?
Coya Therapeutics, Inc. - Common Stock has 47M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS